Navigation Links
BioMS Medical Announces 2009 Year End Results
Date:3/16/2010

Toronto Stock Exchange Symbol: MS

EDMONTON, March 16 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced financial and operational results for the year ended December 31, 2009.

"While 2009 was a challenging year for BioMS and our shareholders, we have remained focused on our core mission of investing our financial and management resources in promising opportunities so as to realize shareholder value," said Kevin Giese, President and CEO of BioMS Medical. "Our investment in Spectral Diagnostics once again provides us with an opportunity to actively participate in the advancement of a pivotal stage product with major market potential, while also leaving resources available to pursue other future opportunities."

    Corporate Update
    ----------------

    -   Subsequent to the end of the year, BioMS invested $12 million in
        Spectral Diagnostics Inc. (TSX: SDI) in exchange for 30,000,000
        common shares of Spectral, representing 39.57% of its issued and
        outstanding common shares.

    -   Spectral has also entered into a three year services agreement where
        BioMS will provide clinical, regulatory and capital markets
        consulting services to Spectral in exchange for $3 million paid to
        BioMS over the term of the contract.

    -   On March 3, 2010, Spectral Diagnostics received Investigational
        Device Exemption (IDE) approval from the 
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
2. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
3. BioMS Medical provides corporate update
4. BioMS Medical Announces Third Quarter 2009 Results
5. BioMS Medical announces second quarter 2009 results
6. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
7. BioMS Medical to participate in panel session at Bio International Convention 2009
8. BioMS Medical Announces First quarter 2009 results
9. BioMS Medical to present at Alberta Economic Forum in Geneva
10. BioMS Medical to present at BioFinance 2009
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... --  Synageva BioPharma Corp. (NASDAQ: GEVA ... disorders, announced today its presentation at the upcoming J.P. ... Francisco, CA. Sanj K. ... on Monday, January 12, 2015, at 9:00 a.m. PST ... and may be accessed from the "Webcasts & Presentations" ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... a DNA diagnostic test to identify women who, may benefit ... ... deCODEme(TM), REYKJAVIK, Iceland, April 27 Scientists from,deCODE genetics (Nasdaq: ... on chromosome 5 of the human genome that are,associated with risk of ...
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that ... stating that the Company is not in,compliance with the ... Nasdaq Global Market pursuant to Marketplace Rule 4450,(a)(5). This ... 22,2008, is a standard communication when the bid price ...
... EXTON, Pa., April 25 Isolagen(TM), Inc.,(Amex: ILE ) ... Global Healthcare Unplugged Conference on Thursday, May 1, 2008 at,3:40 ... May 2, 2008 at the,Ritz-Carlton Key Biscayne in Key Biscayne, ... audio can be accessed by,visiting http://www.isolagen.com . An ...
Cached Biology Technology:deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 5Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... A study published in Cancer Prevention Research ... Cancer Research, identifies components of black raspberries with ... Comprehensive Cancer Center found that anthocyanins, a class ... stimulated apoptosis in the esophagus of rats treated ...
... Aromatase, the key enzyme required for the body to make ... biology work done by the Ghosh lab at the Hauptman-Woodward ... Debashis Ghosh,s solution of the three-dimensional structure of aromatase is ... the mechanism of synthesizing estrogen. In fact, the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3
... human omental preadipocytes are ... otherwise healthy donors. There ... diabetic cells. Please inquire ... media also available. Academic ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
...
Biology Products: